CD3- and CD28-Activating Pathways in HCV Infection

dc.creatorCORADO, JOSÉ A.
dc.creatorTORO, FELIX I.
dc.creatorBAROJA, MIREN L.
dc.creatorBIANCO COLMENARES, NICOLÁS E.
dc.creatorMACHADO, IRMA V.
dc.date2017-02-20T23:40:21Z
dc.date2017-02-20T23:40:21Z
dc.date1994
dc.date.accessioned2022-10-28T01:21:24Z
dc.date.available2022-10-28T01:21:24Z
dc.identifier1557-8976
dc.identifierhttp://hdl.handle.net/10872/14535
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4948159
dc.descriptionWe investigated the proliferative response and IL-2 receptor (IL-2R) expression in peripheral blood mononuclear cells (PBMC) activated with anti-CD3 mAb alone or in combination with anti-CD28 mAb in a group of hepatitis C virus (HCV)-infected patients with detectable viremia demonstrated by "nested" PCR. PBMC from HCV patients and controls showed similar proliferative responses either to anti-CD3 mAb, 64.1, and/or to anti-CD28 mAb, 9.3. No differences were found in anti-CD3 or anti-CD3 plus anti-CD28-induced proliferative responses between patients who demonstrated circulating PBMC bearing HCV-RNA when compared to those with negative HCV-RNA PBMC. Moreover, flow cytometry studies confirmed that anti-CD3 alone or in combination with anti-CD28 were able to induce a significant increase of IL-2R expression in patients or controls PBMC. Both groups showed similar basal CD28 expression. These results indicate that both CD3- and CD28-activating pathways are preserved in HCV-infected patients with chronic active liver disease.
dc.languageen
dc.publisherVIRAL IMMUNOLOGY
dc.relationVol. 7;No. 1 pp 37-40
dc.subjectCD3-
dc.subjectCD28-
dc.subjectmononuclear cells
dc.subjecthepatitis C virus
dc.subjectviremia
dc.subjectlow cytometry
dc.subjectHCV-infected
dc.subjectactiva liver disease
dc.titleCD3- and CD28-Activating Pathways in HCV Infection
dc.typeArticle


Este ítem pertenece a la siguiente institución